{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:18:50Z","timestamp":1783480730836,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-026-00627-z","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:52:53Z","timestamp":1778856773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responses"],"prefix":"10.1038","volume":"15","author":[{"given":"Gao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weize","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojian","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7066-4925","authenticated-orcid":false,"given":"Xiaoming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1342-3405","authenticated-orcid":false,"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"627_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23:92.","journal-title":"Mol Cancer"},{"key":"627_CR2","doi-asserted-by":"crossref","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","DOI":"10.1016\/j.pharmthera.2020.107753"},{"key":"627_CR3","doi-asserted-by":"crossref","unstructured":"Licata L, Dieci MV, De Angelis C, Marchi\u00f2 C, Miglietta F, Cortesi L, et al. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer. Cancer Treat Rev. 2024;128:102762.","DOI":"10.1016\/j.ctrv.2024.102762"},{"key":"627_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ijrobp.2024.01.001","volume":"118","author":"S Verma","year":"2024","unstructured":"Verma S, Young S, Boldt G, Blanchette P, Lock M, Helou J, et al. Immunotherapy and radiation therapy sequencing in breast cancer: a systematic review. Int J Radiat Oncol Biol Phys. 2024;118:1422\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"627_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"627_CR6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: a translational science review. JAMA. 2024;332:1924\u201335.","journal-title":"JAMA"},{"key":"627_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Itahashi K, Nishikawa H. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat Rev Clin Oncol. 2024;21:337\u201353.","journal-title":"Nat Rev Clin Oncol"},{"key":"627_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17:807\u201321.","journal-title":"Cell Mol Immunol"},{"key":"627_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-019-0580-6","volume":"7","author":"KF Bol","year":"2019","unstructured":"Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;7:109.","journal-title":"J Immunother Cancer"},{"key":"627_CR10","doi-asserted-by":"crossref","unstructured":"Hato L, Vizcay A, Eguren I, P\u00e9rez-Gracia JL, Rodr\u00edguez J, P\u00e9rez-Larraya JG, et al. Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 2024;16:981.","DOI":"10.3390\/cancers16050981"},{"key":"627_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/imm.12888","volume":"154","author":"M Collin","year":"2018","unstructured":"Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154:3\u201320.","journal-title":"Immunology"},{"key":"627_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg2752","volume":"379","author":"M He","year":"2023","unstructured":"He M, Roussak K, Ma F, Borcherding N, Garin V, White M, et al. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science. 2023;379:eabg2752.","journal-title":"Science"},{"key":"627_CR13","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","volume":"56","author":"MJ Pittet","year":"2023","unstructured":"Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56:2218\u201330.","journal-title":"Immunity"},{"key":"627_CR14","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1158\/2159-8290.CD-21-0900","volume":"12","author":"X Yuan","year":"2022","unstructured":"Yuan X, Duan Y, Xiao Y, Sun K, Qi Y, Zhang Y, et al. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discov. 2022;12:1742\u201359.","journal-title":"Cancer Discov"},{"key":"627_CR15","doi-asserted-by":"crossref","unstructured":"Varone A, Spano D, Corda D. Shp1 in solid cancers and their therapy. Front Oncol. 2020;10:935.","DOI":"10.3389\/fonc.2020.00935"},{"key":"627_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-immunol-083122-040624","volume":"43","author":"KA Warrick","year":"2025","unstructured":"Warrick KA, Vallez CN, Meibers HE, Pasare C. Bidirectional communication between the innate and adaptive immune systems. Annu Rev Immunol. 2025;43:489\u2013514.","journal-title":"Annu Rev Immunol"},{"key":"627_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70211","volume":"28","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Gao Y, Wang J, Tan X, Liang Y, Yu W, et al. Connexin 43 deficiency confers resistance to immunotherapy in lung cancer via inhibition of the cyclic GMP-AMP synthase-stimulator of interferon genes pathway. J Cell Mol Med. 2024;28:e70211.","journal-title":"J Cell Mol Med"},{"key":"627_CR18","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41596-018-0016-7","volume":"13","author":"G Han","year":"2018","unstructured":"Han G, Spitzer MH, Bendall SC, Fantl WJ, Nolan GP. Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry. Nat Protoc. 2018;13:2121\u201348.","journal-title":"Nat Protoc"},{"key":"627_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","volume":"68","author":"CJ Lim","year":"2019","unstructured":"Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68:916\u201327.","journal-title":"Gut"},{"key":"627_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34:525\u20137.","journal-title":"Nat Biotechnol"},{"key":"627_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89020","volume":"1","author":"Y Carmi","year":"2016","unstructured":"Carmi Y, Prestwood TR, Spitzer MH, Linde IL, Chabon J, Reticker-Flynn NE, et al. Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight. 2016;1:e89020.","journal-title":"JCI Insight"},{"key":"627_CR22","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/cancers17111786","volume":"17","author":"JM Peng","year":"2025","unstructured":"Peng JM, Liu HY. CD300a: an innate immune checkpoint shaping tumor immunity and therapeutic opportunity. Cancers (Basel). 2025;17:1786.","journal-title":"Cancers (Basel)"},{"key":"627_CR23","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/eurheartj\/ehae670","volume":"46","author":"YL Wang","year":"2025","unstructured":"Wang YL, Zhu H, Pan YT, Shang D, Du LJ, Bai L, et al. Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plc\u03b21\/4-Stat5-NF-\u03baB pathway. Eur Heart J. 2025;46:1335\u201351.","journal-title":"Eur Heart J"},{"key":"627_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108468","volume":"33","author":"SC Khouili","year":"2020","unstructured":"Khouili SC, Cook ECL, Hern\u00e1ndez-Garc\u00eda E, Mart\u00ednez-L\u00f3pez M, Conde-Garrosa R, Iborra S. SHP-1 regulates antigen cross-presentation and is exploited by leishmania to evade immunity. Cell Rep. 2020;33:108468.","journal-title":"Cell Rep"},{"key":"627_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/21645515.2019.1653744","volume":"16","author":"DM Richards","year":"2020","unstructured":"Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16:377\u201387.","journal-title":"Hum Vaccin Immunother"},{"key":"627_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1189\/jlb.0103045","volume":"74","author":"N Setterblad","year":"2003","unstructured":"Setterblad N, Roucard C, Bocaccio C, Abastado JP, Charron D, Mooney N. Composition of MHC class II-enriched lipid microdomains is modified during maturation of primary dendritic cells. J Leukoc Biol. 2003;74:40\u20138.","journal-title":"J Leukoc Biol"},{"key":"627_CR27","doi-asserted-by":"crossref","unstructured":"Budd GT, Johnson JM, Rhoades E, Moore H, Levengood H, Kruse M, et al. Phase I trial of alpha-lactalbumin vaccine in high-risk operable triple-negative breast cancer. Cancer Res. 2023;83:3035.","DOI":"10.1158\/1538-7445.AM2023-3035"},{"key":"627_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8:283.","journal-title":"Signal Transduct Target Ther"},{"key":"627_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"627_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"627_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204.","journal-title":"Signal Transduct Target Ther"},{"key":"627_CR32","doi-asserted-by":"crossref","unstructured":"Aqbi HF, Wallace M, Sappal S, Payne KK, Manjili MH. IFN-\u03b3 orchestrates tumor elimination, tumor dormancy, tumor escape, and progression. J Leukoc Biol. 2018;103:1219-1223.","DOI":"10.1002\/JLB.5MIR0917-351R"},{"key":"627_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30:695\u2013704.","journal-title":"Trends Cell Biol"},{"key":"627_CR34","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao LL, Kagan JC. Targeting innate immune pathways for cancer immunotherapy. Immunity. 2023;56:2206\u201317.","journal-title":"Immunity"},{"key":"627_CR35","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41590-022-01131-3","volume":"23","author":"Q Shan","year":"2022","unstructured":"Shan Q, Hu SS, Zhu S, Chen X, Badovinac VP, Peng W, et al. Tcf1 preprograms the mobilization of glycolysis in central memory CD8(+) T cells during recall responses. Nat Immunol. 2022;23:386\u201398.","journal-title":"Nat Immunol"},{"key":"627_CR36","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.18632\/aging.102514","volume":"11","author":"B Chen","year":"2019","unstructured":"Chen B, Lai J, Dai D, Chen R, Li X, Liao N. JAK1 as a prognostic marker and its correlation with immune infiltrates in breast cancer. Aging (Albany NY). 2019;11:11124\u201335.","journal-title":"Aging (Albany NY)"},{"key":"627_CR37","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.4049\/jimmunol.172.4.2307","volume":"172","author":"SH Jackson","year":"2004","unstructured":"Jackson SH, Yu CR, Mahdi RM, Ebong S, Egwuagu CE. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol. 2004;172:2307\u201315.","journal-title":"J Immunol"},{"key":"627_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110420","volume":"38","author":"A Vogel","year":"2022","unstructured":"Vogel A, Martin K, Soukup K, Halfmann A, Kerndl M, Brunner JS, et al. JAK1 signaling in dendritic cells promotes peripheral tolerance in autoimmunity through PD-L1-mediated regulatory T cell induction. Cell Rep. 2022;38:110420.","journal-title":"Cell Rep"},{"key":"627_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"627_CR40","doi-asserted-by":"crossref","unstructured":"Zak J, Teijaro JR. Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy. Nat Rev Immunol. 2026;26:73-74.","DOI":"10.1038\/s41577-026-01266-6"},{"key":"627_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384:eadf1329.","journal-title":"Science"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00627-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00627-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00627-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:12:52Z","timestamp":1783480372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00627-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1038\/s41389-026-00627-z","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Affiliated Qingyuan Hospital of Guangzhou Medical University, approval number: LAEC-2022-027. All animal experiments have complied with ARRIVE Guidelines, the U.K. Animals (Scientific Procedures) Act, 1986 and the EU 2010\/63\/ EU for animal experiments, or the National Research Council\u2019s Guidelines for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"36"}}